PT-141 (Bremelanotide)

PT-141, also known by its chemical name bremelanotide, is a synthetic cyclic heptapeptide derived from the naturally occurring alpha-melanocyte-stimulating hormone (alpha-MSH). It acts as an agonist at melanocortin receptors, particularly MC3R and MC4R, which are expressed in areas of the brain involved in sexual function, including the hypothalamus and limbic system. Unlike many other treatments for sexual dysfunction, PT-141 works centrally -- through the nervous system -- rather than through vascular mechanisms, which distinguishes its pharmacological profile from agents like sildenafil or tadalafil.

PT-141 is typically administered as a subcutaneous injection 45 minutes to 2 hours before anticipated sexual activity. Dosing is individualized and determined by a licensed provider following a clinical review. The peptide's effects have been reported to begin within one to two hours and may persist for several hours. Because it does not rely on vascular signaling, it has been studied in both men and women, including those who have not responded to other approaches to sexual dysfunction.

In clinical study programs, participants reported subjective improvements in sexual desire, arousal, and overall sexual experience. The FDA approved a nasal spray formulation of bremelanotide (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women in 2019, which provides context for the established regulatory and clinical understanding of this compound. Compounded injectable PT-141 is prepared at 503A pharmacies for patients whose licensed providers determine it appropriate after a clinical evaluation.

PT-141 is generally considered a fit for adults who have undergone a clinical assessment for sexual dysfunction and are seeking an option that works through central desire pathways. It may be relevant for individuals who have not found success with other modalities, or for whom vascular-acting agents are not appropriate. As with all compounded peptides dispensed at FormBlends, PT-141 is only provided after a licensed provider reviews your online visit and determines it clinically appropriate.

Common side effects reported in clinical studies include transient nausea, flushing, and headache, typically mild and resolving within hours. Blood pressure monitoring is a relevant safety consideration, as transient increases in blood pressure have been observed. PT-141 is not appropriate for patients with cardiovascular conditions including uncontrolled hypertension, or for those taking antihypertensive medications, without provider guidance. A thorough health history review during your online visit will identify any contraindications.